16 completed, 7 unknown, 6 recruiting, 4 active not recruiting. 35 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 35 | Completed 16, Unknown 7, Recruiting 6, Active not recruiting 4, Terminated 2 |
| Phase 2 | 7 | Completed 2, Unknown 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Lomustine: new trials by email Literature Review of Lomustine trials Research Report on Lomustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma TLX-101-Tx + Lomustine, TLX101-Tx - Neoplastic Disease, Glioblastoma | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 50 | 2025-11-02 | 2026-08-11 |
| Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma Temozolomide, Lomustine - Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma | Phase 3 | Recruiting | Vastra Gotaland Region | 200 | 2025-02-01 | 2026-04-13 |
| Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study Lomustine, Reirradiation - First Progression of Glioblastoma | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 411 | 2024-03-15 | 2026-06-08 |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM SonoCloud-9 (SC9), Carboplatin, Lomustine - Glioblastoma, Recurrent Glioblastoma | Phase 3 | Active not recruiting | CarThera | 560 | 2024-01-29 | 2026-11-05 |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss Audiometric Test, Auditory Brainstem Response, Biospecimen Collection - Childhood Medulloblastoma | Phase 3 | Recruiting | Children's Oncology Group | 225 | 2023-02-20 | 2026-08-25 |
| Tofacitinib in Recurrent GBM Patients Tofacitinib 10mg, Temozolomide, Lomustine - Glioblastoma | Phase 3 | Completed | University of Texas Southwestern Medical Center | 18 | 2022-10-07 | 2026-06-29 |
| Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy - Glioblastoma, Gliosarcoma | Phase 3 | Active not recruiting | NRG Oncology | 265 | 2022-03-28 | 2026-08-17 |
| A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). CETEG, PCV, RT - Oligodendroglioma | Phase 3 | Recruiting | University Hospital Heidelberg | 406 | 2021-04-07 | 2026-02-03 |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Temozolomide, Lomustine, Regorafenib - Glioblastoma | Phase 2 / Phase 3 | Recruiting | Global Coalition for Adaptive Research | 2250 | 2019-07-30 | 2026-11-02 |
| Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients Chlorogenic acid for Injection, Lomustine - GBM | Phase 2 / Phase 3 | Unknown | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | 200 | 2018-11-27 | 2018-11-29 |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Sunitinib, Lomustine - Glioblastoma Multiforme, Glioblastoma, Adult | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 100 | 2018-08-31 | 2021-04-19 |
| Disulfiram in Recurrent Glioblastoma Disulfiram, Copper, Alkylating Agents - Glioma, Glioblastoma | Phase 2 / Phase 3 | Completed | Sahlgrenska University Hospital | 88 | 2017-01-01 | 2021-03-18 |
| Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Eflornithine, Lomustine - Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma | Phase 3 | Unknown | Orbus Therapeutics, Inc. | 343 | 2016-07-01 | 2022-01-21 |
| The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Toca 511, Toca FC, Lomustine - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 2 / Phase 3 | Terminated | Tocagen Inc. | 403 | 2015-11-30 | 2020-02-07 |
| International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma Radiotherapy without Carboplatin, Reduced-intensity maintenance chemotherapy, Radiotherapy with Carboplatin - Brain Tumors | Phase 2 / Phase 3 | Active not recruiting | Universitätsklinikum Hamburg-Eppendorf | 360 | 2014-06-01 | 2025-12-04 |
| Bevacizumab and Lomustine for Recurrent GBM bevacizumab, lomustine, DNA methylation analysis - Glioblastoma Multiforme, Cognition Disorders | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 592 | 2011-10-01 | 2021-02-15 |
| Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Temozolomide and lomustine, Temozolomide - Glioblastoma | Phase 3 | Completed | University Hospital, Bonn | 141 | 2010-10-01 | 2017-06-14 |
| Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma concomitant temozolomide (TMZ), radiotherapy, procarbazine - Brain and Central Nervous System Tumors | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 305 | 2009-09-01 | 2026-01-22 |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma trabedersen, temozolomide, Drug delivery system for administration of AP 12009 - Anaplastic Astrocytoma, Glioblastoma | Phase 3 | Terminated | Isarna Therapeutics GmbH | 27 | 2008-12-01 | 2014-11-14 |
| Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old Lomustine - Acute Myeloid Leukemia | Phase 3 | Completed | University Hospital, Bordeaux | 459 | 2008-02-01 | 2014-04-02 |
Showing 20 of 35. Sign in to see all of them.
Glioblastoma (17) · Central Nervous System Neoplasms (12) · Brain Neoplasms (11) · Astrocytoma (10) · Glioma (7) · Oligodendroglioma (5) · Gliosarcoma (3) · Medulloblastoma (3) · Leukemia, Myeloid, Acute (2) · Neoplasms (2) · Recurrence (2) · Cognition Disorders (1) · Multiple Myeloma (1) · Neoplasm Recurrence, Local (1) · Neoplasms, Plasma Cell (1)
Children's Oncology Group (4) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Radiation Therapy Oncology Group (3) · Alliance for Clinical Trials in Oncology (1) · Amsterdam UMC, location VUmc (1) · CarThera (1) · Colorado Health Foundation (1) · Eli Lilly and Company (1) · French Innovative Leukemia Organisation (1) · German Society for Pediatric Oncology and Hematology GPOH gGmbH (1) · Global Coalition for Adaptive Research (1) · Institute of Cancer Research, United Kingdom (1) · Isarna Therapeutics GmbH (1) · NRG Oncology (1) · Orbus Therapeutics, Inc. (1)
United States (18) · Canada (13) · France (13) · Netherlands (13) · Germany (12) · Austria (10) · Belgium (9) · Italy (8) · Switzerland (8) · United Kingdom (8) · Australia (7) · Spain (7) · Sweden (6) · Denmark (4) · Norway (4)
Amar Gajjar, MD (1) · Arnaud Pigneux, MD, PhD (1) · Asgeir S Jakola, MD, PhD (1) · Brigitta Lannering, MD, PhD (1) · Christoph Kramm, MD (1) · Diana Samson, MD (1) · Edward G. Shaw, MD (1) · Fabio M Iwamoto (1) · Francois Doz, Prof. Dr. (1) · Fred W. Hetzel, PhD, JD (1) · Geoffrey R. Barger, MD (1) · Giuseppe Minniti, Dr. (1) · J. Gregory Cairncross, MD (1)
PMID 35731991, PMID 11586105, PMID 15234047, PMID 16782910, PMID 16782911, PMID 16943538, PMID 17549014, PMID 18089866, PMID 18089867, PMID 18371182, PMID 18976072, PMID 19224764, PMID 19783377, PMID 19901104, PMID 20124186, PMID 20160062, PMID 20694800, PMID 20820870, PMID 20855843, PMID 21246521, PMID 21914791, PMID 22665535, PMID 22851558, PMID 23071237, PMID 23071247, PMID 23269986, PMID 24419119, PMID 27050206, PMID 27252174, PMID 27744512, PMID 29141164, PMID 29393183, PMID 30647912, PMID 30782343, PMID 31386061, PMID 31488360, PMID 32706640, PMID 32943750, PMID 33113214, PMID 33119048, PMID 34110925, PMID 35692047, PMID 36609807, PMID 37000452, PMID 38773224, PMID 38849943, PMID 40967259, PMID 41325560, PMID 41980234
2023 (2), U10CA180886 (2), 2009 (1), 2018 (1), 2025 (1), U10CA098543 (1), U10CA180868 (1)